Muckle–Wells syndrome: clinical perspectives

Muckle–Wells syndrome: clinical perspectives

Tu-Anh Tran Department of Pediatrics, Nîmes University Hospital, INSERM U1183, Montpellier-Nîmes University, Nîmes, France Abstract: Muckle–Wells syndrome (MWS) is a rare autoinflammatory disorder. It is due to NLRP3 gene mutations, responsible for excessive c...

Full description

Bibliographic Details
Main Author:	Tran TA
Format:	Article
Language:	English
Published:	Dove Medical Press 2017-07-01
Series:	Open Access Rheumatology : Research and Reviews
Subjects:	Muckle-Wells syndrome anti-interleukin 1 anakinra rilonacept canakinumab clinical presentation
Online Access:	https://www.dovepress.com/muckle-wells-syndrome-clinical-perspectives-peer-reviewed-article-OARRR

Similar Items

IL-1 Inhibitors in the Treatment of Monogenic Periodic Fever Syndromes: From the Past to the Future Perspectives
by: Hana Malcova, et al.
Published: (2021-02-01)

Resolution of unilateral sensorineural hearing loss in a pediatric patient with a severe phenotype of Muckle-Wells syndrome treated with Anakinra: a case report and review of the literature
by: Cinzia Marchica, et al.
Published: (2018-01-01)

Management of adult-onset Still’s disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts
by: Serena Colafrancesco, et al.
Published: (2019-12-01)

The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives
by: Toplak N, et al.
Published: (2018-06-01)

A familial case of Muckle-Wells syndrome in a Russian population: The first successes of therapy with the interleukin 1 inhibitor canakinumab
by: S. O. Salugina, et al.
Published: (2015-03-01)

IL-1 inhibition in systemic juvenile idiopathic arthritis
by: Gabriella Giancane, et al.
Published: (2016-12-01)

Muckle–Wells Syndrome in a Child With Recurrent Urticaria
by: Elena M. Kamaltynova, et al.
Published: (2017-06-01)

Decreased quality of life and societal impact of cryopyrin-associated periodic syndrome treated with canakinumab: a questionnaire based cohort study
by: Catharina M. Mulders-Manders, et al.
Published: (2018-04-01)

Somatic NLRP3 mosaicism in Muckle-Wells syndrome. A genetic mechanism shared by different phenotypes of cryopyrin-associated periodic syndromes
by: Nakagawa, Kenji
Published: (2016)

Muckle-Wells syndrome in an Indian family associated with NLRP3 mutation
by: M C Abdulla, et al.
Published: (2015-01-01)

An Unusual Case of Allergic Reaction to Anakinra in a Patient with Tumor Necrosis Factor Receptor-1 Associated Periodic Syndrome (TRAPS) and Subsequent Canakinumab Treatment
by: Marta Mejias Trueba, et al.
Published: (2020-07-01)

Hyperphosphatemic Familial Tumoral Calcinosis With Galnt3 Mutation: Transient Response to Anti‐Interleukin‐1 Treatments
by: Astrid Dauchez, et al.
Published: (2019-07-01)

MUCKLE-WELLS SYNDROME CAUSED BY A NEW CRYOPIRIN MUTATION: EFFECTIVE TREATMENT WITH INTERLEUKIN-1 ANTAGONIST
by: V V Rameev, et al.
Published: (2012-06-01)

Muckle-Wells Syndrome Across Four Generations in One Czech Family: Natural Course of the Disease
by: Šárka Fingerhutová, et al.
Published: (2019-04-01)

A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study
by: Antonio Vitale, et al.
Published: (2016-10-01)

Failure of anti Interleukin-1 β monoclonal antibody in the treatment of recurrent pericarditis in two children
by: Sara Signa, et al.
Published: (2020-06-01)

A Novel Mutation in the Pyrin Domain of the NOD-like Receptor Family Pyrin Domain Containing Protein 3 in Muckle-Wells Syndrome
by: Jian Hu, et al.
Published: (2017-01-01)

The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review
by: Véronique Hentgen, et al.
Published: (2020-05-01)

Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide
by: Alessandra Soriano, et al.
Published: (2020-06-01)

Neonatal onset multisystem inflammatory disease (NOMID): Case report
by: Urška Berden, et al.
Published: (2016-02-01)

Successful treatment of refractory hyperferritinemic syndromes with canakinumab: a report of two cases
by: Riccardo Papa, et al.
Published: (2020-07-01)

Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still’s Disease: A Multicentre Retrospective Observational Study
by: Serena Colafrancesco, et al.
Published: (2017-06-01)

The Role of Interleukin-1 in the Pathogenesis of Cancer and its Potential as a Therapeutic Target in Clinical Practice
by: Adi Litmanovich, et al.
Published: (2018-11-01)

Systemic autoinflammation with intractable epilepsy managed with interleukin-1 blockade
by: Allen D. DeSena, et al.
Published: (2018-02-01)

Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis – data from the German AID-registry
by: Elke Lainka, et al.
Published: (2021-03-01)

Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents
by: Giorgio Costagliola, et al.
Published: (2021-05-01)

Familial Mediterranean Fever: Current Approaches to Diagnosis and Treatment
by: Mikhail M. Kostik, et al.
Published: (2018-12-01)

Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis
by: Jurgen Sota, et al.
Published: (2019-01-01)

FAMILIAL MEDITERRANEAN FEVER: ASSESSING THE OVERALL CLINICAL IMPACT AND FORMULATING TREATMENT PLANS
by: Donato Rigante, et al.
Published: (2019-04-01)

Editorial: IL-1 Inhibition
by: Francesca Oliviero, et al.
Published: (2019-02-01)

A Case of Hearing Impairment with Renal Dysfunction
by: G K Prakash, et al.
Published: (2021-01-01)

Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever
by: Ali Şahin, et al.
Published: (2020-01-01)

The interleukin 1 inhibitor canakinumab in the treatment of cryopyrin-associated periodic syndromes (CAPS): clinical experience
by: Svetlana Olegovna Salugina, et al.
Published: (2014-12-01)

Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
by: Gerd Horneff, et al.
Published: (2017-11-01)

Improvement of liver involvement in familial Mediterranean fever after introduction of canakinumab: a case report
by: Maria Grazia Massaro, et al.
Published: (2020-08-01)

DIAGNOSIS AND TREATMENT OF PATIENTS WITH CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME
by: A. L. Kozlova, et al.
Published: (2015-04-01)

EXPERIENCE OF THE SUCCESSFUL CANAKINUMAB TREATMENT OF A PATIENT WITH UNDIFFERENTIATED AUTOINFLAMMATORY SYNDROME
by: Tatyana V. Sleptsova, et al.
Published: (2016-11-01)

Effects of interleukin-1 antagonism on cortisol levels in individuals with obesity: a randomized clinical trial
by: Fahim Ebrahimi, et al.
Published: (2019-05-01)

Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases
by: Alessandra Bettiol, et al.
Published: (2019-04-01)

A case of Schnitzler’s syndrome without monoclonal gammopathy successfully treated with canakinumab
by: Yuya Fujita, et al.
Published: (2021-03-01)

Cannot write session to /tmp/vufind_sessions/sess_16qq10mv04cvo18p1ohskkvs18